CD1D and plasma cell myeloma: Here, we generated a CD1d-Vδ2 bsTCE that can trigger robust activation of both type 1 NKT and Vγ9Vδ2-T cells toward CD1d+ tumor cells, resulting in strong activity in in vivo models and ex vivo against patient multiple myeloma (MM), monocytic acute myeloid leukemia (AML), and chronic lymphocytic leukemia (CLL) cells.